TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06373159

Intervention type: OTHER
Intervention: No study intervention
Description: Retrospective observational study using Real World Data (RWD) in Japan without study intervention

Intervention type: OTHER
Intervention: No study intervention
Description: Retrospective observational study using Real World Data (RWD) in Japan without study intervention

Intervention type: OTHER
Intervention: No study intervention
Description: Retrospective observational study using Real World Data (RWD) in Japan without study intervention
Study: NCT06557733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP2/EP4 Antagonist TPST-1495
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Endoscopy
Description: Undergo GI endoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06164587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K8
Description: sustained released intravitreal implants
Study: NCT04682106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salcaprozate Sodium
Description: Administered orally.
Study: NCT05932134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UC + high protein diet (HP)
Description: The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UC + HP + core muscle rehabilitation
Description: Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)
Description: NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
Study: NCT06417892

Intervention type: DRUG
Intervention: PD-1inhibitor
Description: PD-1 antibody was selected according to first-line drug use

Intervention type: DRUG
Intervention: Fruquintinib
Description: a small molecular anti-tumor angiogensis drug

Intervention type: DRUG
Intervention: Fruquintinib
Description: a small molecular anti-tumor angiogensis drug

Intervention type: DRUG
Intervention: albumin paclitaxel
Description: a kind of cytotoxic chemotherapy drug

Intervention type: DRUG
Intervention: albumin paclitaxel
Description: a kind of cytotoxic chemotherapy drug
Study: NCT06581536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yes and Know curriculum
Description: Yes and Know is fully virtual intervention that integrates group-based education with digital tools to support young people ages 14 to 19 by increasing their relationship and healthy life skills. The curriculum focuses on sexual and reproductive health; healthy relationships; life skills; and educational and career success. It is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education for Adolescents
Description: Youth will receive a fully virtual intervention that integrates group-based education with digital tools focused on adolescent nutrition and wellness. The curriculum is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
Study: NCT06091254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous infusion (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered by IV, or subcutaneously (SC)
Study: NCT05238506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intraoperative intravenous lidocaine infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Intraoperative intravenous normal saline infusion.
Study: NCT05496114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Checklist
Description: A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
Study: NCT06091254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered by IV as part of CHOP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered by IV as part of CHOP, and CVP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/prednisolone
Description: Administered orally (PO) as part of CVP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Administered by IV as part of chemotherapy (Rituximab-Bendamustine)
Study: NCT06209203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lowe-dose ZKY001 eye drops
Description: eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose ZKY001 eye drops
Description: eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: eye drops
Study: NCT05822583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept infusion
Description: The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group (IV infusion of normal saline) + baseline IM
Study: NCT06149676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG [Florastor]
Description: All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
Study: NCT06199921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Participants will receive oral atorvastatin 20mg daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: Participants will receive oral atorvastatin 40mg daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60mg
Description: Participants will receive oral atorvastatin 60 mg daily for 16 weeks
Study: NCT06246110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIK1001
Description: EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIK1001
Description: EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study: NCT05697146

Intervention type: OTHER
Intervention: ribociclib + ET
Description: There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
Study: NCT05783609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: T-cell bispecific antibody, via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD20 monoclonal antibody, via IV infusion
Study: NCT04635098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: All participants will be randomly assigned to receive either dexmedetomidine or saline
Study: NCT05514847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81Mg Ec Tab
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162Mg Ec Tab
Description: 162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162Mg Ec Tab
Description: 162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study: NCT05187182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-4948
Description: Provided by Curis, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-4948
Description: Provided by Curis, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-4948
Description: Provided by Curis, Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg IV on Day 1 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg IV on Day 1 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,...) and dosing may continue for a max of 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
Study: NCT06721585

Intervention type: OTHER
Intervention: Standard of Care (SOC)
Description: Participants are provided SOC for mpox
Study: NCT06719713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Store Safely
Description: The Store Safely intervention occurs online and is self-administered. Once directed to the Store Safely website, participants are welcomed and instructed to complete each step of the online program. Upon clicking Start, participants are taken to Step 1 of the intervention and instructed to review a brief video. Step 2 involves a review of a data infographics. Participants are then directed to the Decision Aid in Step 3. In Step 4, participants are instructed to complete the Family Firearm Storage Action Plan. In Step 5, participants will review another brief video. There will also be an optional step, consisting of a resource page that details local options for obtaining safe storage devices. At the end of each step, participants mark a checkbox to indicate they have completed the intervention activity which facilitates website analytics of participant engagement. Lastly, participants are thanked and provided with details about the final steps of the trial.
Study: NCT05187182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX7
Description: Standard of care
Study: NCT04732403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Position
Description: The patient will be placed in an angle on the surgical table during cystoscopy.
Study: NCT05041023

Intervention type: OTHER
Intervention: Relative section
Description: Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death.

Intervention type: OTHER
Intervention: Caregiver section
Description: Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist.
Study: NCT05716139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Cycle
Description: The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Artificial Cycle
Description: Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
Study: NCT06328361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative surveillance
Description: Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
Study: NCT05424549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed six times over two consecutive days
Study: NCT04723875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or docetaxel + Cisplatin or carboplatin
Description: Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study: NCT05362903

Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.

Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
Study: NCT06444087

Intervention type: OTHER
Intervention: secukinumab
Description: This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Study: NCT06413537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPG601
Description: synthetic small molecule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04623216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Sabatolimab is a solution in vial for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine comes in Vial for IV infusion or subcutaneous administration
Study: NCT06502379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8965
Description: AZD8965 will be administered orally.
Study: NCT06721442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
Study: NCT06720090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: 5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light therapy
Description: 5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
Study: NCT06317259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoxic breathwork plus music and messaging
Description: Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic breathwork only
Description: Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music and messaging meditation
Description: Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
Study: NCT04267393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05630794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy